Searched for
USFDA CLEARANCE
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- Strides Pharma gets USFDA nod for generic ointment to treat skin conditionsStrides Pharma Science on Tuesday said it has received US health regulator's approval for its generic version of triamcinolone acetonide oi...
- Sun Pharma shares rally after USFDA reclassifies Halol Unit as 'No Action Initiated'USFDA no action initiated status means clearance for the unit.
- Strides Shasun up over 3% on USFDA clearanceStrides Shasun is a vertically integrated global pharmaceutical company headquartered in Bengaluru.
- Sun Pharma up 3% on USFDA clean chit to Halol plantThe clearance brought to an end a two-year import ban the US drug regulator had imposed.
- Dr Reddy’s Labs rises even as API plant receives 3 USFDA observationsThe stock, however, was trading with a positive bias in the morning trade. It rose 0.89 per cent to hit a high of Rs 2,919 on BSE.
- Sell Lupin Ltd. with a target of Rs 1500 – CLSAThe global investment bank sees muted EPS growth in FY18 as top products get competitive and is expected to further pick-up over the next f...
- Strides Shasun gets tentative nod from USFDA for Roflumilast tabletsThe product will manufacture the product in Bengaluru, has received approval in 15 months under the USFDA new product clear regime.
- Strides Shasun gets USFDA nod for anti-biotic and anti-protozoal tabletsThe product received approval in 17 months under the USFDA's new product clearance regime of GDUFA. The product is ready for immediate laun...
- Beaten down pharma stocks provide buying opportunity: Deven ChokseySo, to my mind there is no doubt about it, even as an investor you would like to see the situation going forward remaining stable for these...
- Opto Circuits rallies as company gets USFDA clearance to market new AEDOpto Circuits surged as much as 14.21 per cent in intraday trade after its group company Cardiac Science Corporation got market clearance.
- USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term?Manufacturing-related indiscretions of Indian firms put a question mark on prospects for generics exports.
- Aurobindo Pharma may get USFDA nod for new facility: SourcesAurobindo Pharma seems all set to get approval from the USFDA for its new Hyderabad-based Unit IV facility, say sources.
- Morgan Stanley, Barclays buy Claris bulk shares in open market on USFDA clearanceClaris said it has formally received the letter from USFDA stating that it has completed its evaluation of the firm's corrective actions.
- Claris Lifesciences net profit falls 14%, USFDA clearance awaitingThe consolidated net profit stood at Rs 32.32 crore for second quarter ended on 30 June 2012 compared to Rs 37.72 crore for the same period...
- USFDA lifts ban on Dr Reddy's Laboratories' Mexico plantDrug firm Dr Reddy's Laboratories today said the US health regulator has lifted an import alert issued on its Mexico-based subsidiary.
- Claris Lifesciences yet to get USFDA clearanceClaris Lifesciences said its consolidated net profit rose 9% for the first quarter of calendar year 2012 to Rs 21.7 crore.
- Sharekhan puts buy on LupinSharekhan has come out with a ‘buy’ on Lupin on account of its differentiated business model with global dominance in certain products, foc...
Load More
